文献速递白血病

糖基转移酶ST3GAL4通过合成Siglec-9配体驱动急性髓系白血病免疫逃逸

The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9.
PubMed 文献 · Leukemia · 2024-11-17

本研究探讨急性髓系白血病(AML)细胞表面聚糖在免疫逃逸中的作用。AML细胞高水平表达Siglec-9配体,整合CRISPR基因组筛选与临床生物信息学分析鉴定ST3GAL4为Siglec-9配体表达的潜在驱动因子。CRISPR-Cas9敲除ST3GAL4大幅降低AML细胞Siglec-9配体表达,质谱分析显示Siglec-9主要结合N-连接唾液酸聚糖,ST3GAL4敲除增强AML细胞对表达Siglec-9巨噬细胞的吞噬敏感性。

要点

  • AML细胞高水平表达抑制性受体Siglec-9的配体。
  • ST3GAL4被鉴定为AML中Siglec-9配体表达的潜在驱动因子。
  • ST3GAL4敲除增强AML细胞对Siglec-9巨噬细胞的吞噬敏感性。

核心结论

  • 本研究揭示了一条新的免疫逃逸轴,并提示ST3GAL4可能成为AML免疫治疗的靶点。

研究设计与样本

  • 研究采用CRISPR基因组筛选、临床生物信息学分析、CRISPR-Cas9敲除、质谱分析及吞噬实验等方法。

主要发现

  • AML细胞高水平表达Siglec-9配体。
  • 整合CRISPR基因组筛选与临床生物信息学分析鉴定ST3GAL4为AML中Siglec-9配体表达的潜在驱动因子。
  • CRISPR-Cas9敲除ST3GAL4大幅降低AML细胞Siglec-9配体表达。
  • 质谱分析显示Siglec-9主要结合这些细胞类型上的N-连接唾液酸聚糖。
  • ST3GAL4敲除增强AML细胞对表达Siglec-9巨噬细胞的吞噬敏感性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunotherapy has demonstrated promise as a treatment for acute myeloid leukemia (AML). However, there is still an urgent need to identify new molecules that inhibit the immune response to AML. Most prior research in this area has focused on protein-protein interaction interfaces. While carbohydrates also regulate immune recognition, the role of cell-surface glycans in driving AML immune evasion is comparatively understudied. The Siglecs, for example, are an important family of inhibitory, glycan-binding signaling receptors that have emerged as prime targets for cancer immunotherapy in recent years. In this study, we find that AML cells express ligands for the receptor Siglec-9 at high levels. Integrated CRISPR genomic screening and clinical bioinformatic analysis identified ST3GAL4 as a potential driver of Siglec-9 ligand expression in AML. Depletion of ST3GAL4 by CRISPR-Cas9 knockout (KO) dramatically reduced the expression of Siglec-9 ligands in AML cells. Mass spectrometry analysis of cell-surface glycosylation in ST3GAL4 KO cells revealed that Siglec-9 primarily binds N-linked sialoglycans on these cell types. Finally, we found that ST3GAL4 KO enhanced the sensitivity of AML cells to phagocytosis by Siglec-9-expressing macrophages. This work reveals a novel axis of immune evasion and implicates ST3GAL4 as a possible target for immunotherapy in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Krishnamoorthy V, Daly J, Kim J, et al. The glycosyltransferase ST3GAL4 drives immune evasion in acute myeloid leukemia by synthesizing ligands for the glyco-immune checkpoint receptor Siglec-9. Leukemia. 2024. PMID: 39551873. doi:10.1038/s41375-024-02454-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。